Quantitative Amyloid imaging in autosomal Dominant Alzheimer's disease: Results from the DIAN study group

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Su, Yi ^a   Blazey, Tyler M ^a   Owen, Christopher J ^a   Christensen, Jon J ^a   Friedrichsen, Karl ^a   Joseph Mathurin, Nelly ^a   Wang, Qing ^a   Hornbeck, Russ C ^a   Ances, Beau M ^b   Snyder, Abraham Z ^a,b   Cash, Lisa A ^a   Koeppe, Robert A ^c   Klunk, William E ^d   Galasko, Douglas ^e   Brickman, Adam M ^f   McDade, Eric ^b   Ringman, John M ^g   Thompson, Paul M ^g   Saykin, Andrew J ^h   Ghetti, Bernardino ^h   Sperling, Reisa A ⁱ   Johnson, Keith A ⁱ   Salloway, Stephen P ^j   Schofield, Peter R ^k   Masters, Colin L ^l   Villemagne, Victor L ^l   Fox, Nick C ^m   Förster, Stefan ⁿ   Chen, Kewei ^o   Reiman, Eric M ^o   Xiong, Chengjie ^b   Marcus, Daniel S ^a   Weiner, Michael W ^p   Morris, John C ^b   Bateman, Randall J ^b   Benzinger, Tammie L S ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Indiana University ^*  (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j BROWN UNIVERSITY   (United States)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o BANNER ALZHEIMER S INSTITUTE   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; PITTSBURGH COMPOUND B; CARBON;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOSOMAL DOMINANT ALZHEIMER DISEASE; AUTOSOMAL DOMINANT DISORDER; BRAIN STEM; CEREBELLUM CORTEX; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE MUTATION; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; WHITE MATTER; BRAIN; CHEMISTRY; DIAGNOSTIC IMAGING; DNA MUTATIONAL ANALYSIS; DOMINANT GENE; FAMILY HEALTH; GENETICS; HETEROZYGOTE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; MUTATION; REFERENCE VALUE;

ADULT; ALZHEIMER DISEASE; AMYLOID; BRAIN; CARBON ISOTOPES; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENES, DOMINANT; HETEROZYGOTE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES;

EID: 84962109872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152082     Document Type: Article

References (41)

1. Holtzman DM, Morris JC, Goate AM Alzheimer's Disease: The Challenge of the Second Century. Science Translational Medicine 2011;3:77sr71-77sr71.
2. Alzheimer's A 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014;10:e47-92. PMID: 24818261
3. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N EnglJ Med 2012;367:795-804. doi: 10.1056/NEJMoa1202753 PMID: 22784036
4. Benzinger TL, Blazey T, Jack CR Jr., Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A 2013;110:E4502-4509. doi: 10.1073/pnas.1317918110 PMID: 24194552
5. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011;76:280-286. doi: 10.1212/WNL. 0b013e318207b1b9 PMID: 21178097
6. Aisen PS Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther 2009;1:2. doi: 10.1186/alzrt2 PMID: 19674435
7. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 2014;275:251-283. doi: 10.1111/joim.12191 PMID: 24605808
8. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013;169:737-743.
9. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? SciTransl Med 2014;6:228fs213.
10. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26 Suppl 3:321-329. doi: 10.3233/JAD-2011-0059 PMID: 21971471
11. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIBinanondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452. PMID: 16894106
12. Su Y, DAngelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative analysis of PiB-PET with Free SurferROIs. PLoS One 2013;8:e73377. doi: 10.1371/journal.pone.0073377 PMID: 24223109
13. Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 1996;46:406-412. PMID: 8614503
14. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001;158:2165-2175. PMID: 11395394
15. Edison P, Hinz R, Ramlackhansingh A, Thomas J, Gelosa G, Archer HA, et al. Can target-to-pons ratio be used as a reliable method for the analysis of [(11) C]PIB brain scans? Neuroimage 2012;60:1716-1723. doi: 10.1016/j.neuroimage.2012.01.099 PMID: 22306804
16. Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18) F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage 2015;108:450-459. doi: 10.1016/j.neuroimage.2014.11.055 PMID: 25482269
17. Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med 2015;56:560-566. doi: 10.2967/jnumed.114.149732 PMID: 25745091
18. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 2015;107:55-64. doi: 10.1016/j.neuroimage.2014.11.058 PMID: 25485714
19. Soret M, Bacharach SL, Buvat I Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-945. PMID: 17504879
20. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40:2053-2065. PMID: 10616886
21. Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2011;38:1104-1119. doi: 10.1007/s00259-011-1745-9 PMID: 21336694
22. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959-1972. PMID: 16330558
23. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL Distribution volume ratios without blood sampling from graphical analysis of PET data. Journal of Cerebral Blood Flow and Metabolism 1996;16:834-840. PMID: 8784228
24. Lammertsma AA, Hume SP Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-158. PMID: 9345505
25. Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of Longitudinal beta-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios. J Nucl Med 2015;56:567-574. doi: 10.2967/jnumed.114.148981 PMID: 25745095
26. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2:975-984.
27. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706. PMID: 1671712
28. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760. PMID: 7596406
29. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-977. PMID: 7638622
30. Su Y, Blazey TM, Snyder AZ, Raichle ME, Hornbeck RC, Aldea P, et al. Quantitative amyloid imaging using image-derived arterial input function. PLoSOne 2015;10:e0122920. doi: 10.1371/journal.pone. 0122920 PMID: 25849581
31. Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
32. Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, Garcia G, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280APS1 kindred. Ann Neurol 2003;54:163-169. PMID: 12891668
33. Rousset OG, Collins DL, Rahmim A, Wong DF Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med 2008;49:1097-1106. doi: 10.2967/jnumed.107.048330 PMID: 18552147
34. Su Y, Arbelaez AM, Benzinger TL, Snyder AZ, Vlassenko AG, Mintun MA, et al. Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow. J Cereb Blood Flow Metab 2013;33:115-121. doi: 10.1038/jcbfm.2012.143 PMID: 23072748
35. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747. PMID: 2384545
36. van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 2013;54:1570-1576. doi: 10.2967/jnumed.112.113654 PMID: 23940304
37. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-384. doi: 10.2967/jnumed.111.090340 PMID: 22331215
38. Bilgel M, Carass A, Resnick SM, Wong DF, Prince JL Deformation field correction for spatial normalization of PET images. Neuroimage 2015;119:152-163. doi: 10.1016/j.neuroimage.2015.06.063 PMID: 26142272
39. Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, Rowe C, et al. Automated (11) C-PiBstandardized uptake value ratio. Acad Radiol 2008;15:1376-1389. doi: 10.1016/j.acra.2008.07.006 PMID: 18995189
40. Tohka J, Reilhac A Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method. Neuroimage 2008;39:1570-1584. PMID: 18077187
41. Panin VY, Kehren F, Michel C, Casey M Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging 2006;25:907-921. PMID: 16827491